DOI (2,5-Dimethoxy-4-iodoamphetamine)

Category: Psychedelics. Status: Schedule I (research compound).

A DOx psychedelic widely used in neuroscience labs as a research tool to study serotonin 5-HT2A receptors, in addition to its psychedelic effects.

How it works

A potent, long-acting 5-HT2A receptor agonist; a standard pharmacology research tool.

Key facts

• Molecular weight: 321.16 g/mol
• Half-life: Long
• Bioavailability: Oral
• Storage: Research/reference only.

Dosing overview

• Typical dose: Varies by individual and setting
• Frequency: Occasional
• Duration: Acute effects last 12-24 hours
• Route: Oral

Protocol notes

• Mostly used in laboratories as a research tool to study serotonin receptors.
• When taken by people it is oral and extremely long-acting.

Reported benefits

• Key laboratory research tool
• Long-acting psychedelic
• Used to map 5-HT2A receptors
• DOx family

Possible side effects

• Very long duration
• Vasoconstriction
• Anxiety
• Raised blood pressure

Compare DOI

• DOI vs MDMA
• DOI vs Psilocybin
• DOI vs LSD
• DOI vs Ibogaine
• DOI vs DMT
• DOI vs Ayahuasca

Community discussions about DOI

• beginner questions on rapamycin and metformin for longevity - 6 comments
• Ovagen injectable site reactions and rotation protocol - 6 comments
• Trying a low‑dose KLOW‑lite for post‑run recovery – need timing feedback - 4 comments
• FDA scientists flag peptide safety gaps, and I think that matters - 4 comments
• How I used TB‑500 around my rotator cuff rehab - 4 comments
• Ask the community about DOI

Research and educational reference only. Not medical advice.